Halozyme Therapeutics, Inc. provides earnings guidance for the year 2024. For the period, the company expects Total revenue of $915 million to $985 million, representing growth of 10% to 19% over 2023 total revenue primarily driven by increases in royalty revenue, collaboration revenue and growth in product sales from XYOSTED. Revenue from royalties of $500 million to $525 million, representing growth of 12% to 17% over 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.57 USD | +0.29% | -0.18% | +4.36% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.36% | 4.9B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024